Alnylam Pharmaceuticals (ALNY)
(Delayed Data from NSDQ)
$276.33 USD
+3.18 (1.16%)
Updated Sep 19, 2024 04:00 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Brokerage Reports
0 items in cart
Alnylam Pharmaceuticals, Inc. [ALNY]
Reports for Purchase
Showing records 21 - 40 ( 421 total )
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Statistical Plan Changes in HELIOS-B Positioning AMVUTTRA for Market Leadership in ATTR-CM; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Hepatitis B Breakthrough Boom: Navigating a $450-$500 Billion Frontier
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Key Takeaways from Biotech Breakthroughs ATTR-CM Event: Expect HELIOS-B to Meet Primary, Secondary Endpoints; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Solid Finish to 2023 Ahead of Pivotal Phase 3 TTR Data Expected in Early 2024; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Genomic Medicine Deep Dive-Redrawing Frontiers at the Coding Level
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Next Wave of RNAi Therapeutics to Expand Pipeline With Focus on CNS; Phase 3 HELIOS-B Data on Deck; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for ALNY 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Long-Term Phase 2 Data Show Sustained Benefit with Zilebesiran in Hypertension; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Results; Maintains 2023 Sales Guidance; Announces RD Day; TTR, HBV Programs Near Catalysts to Drive Upside
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Promising Data Continues to Emerge From ALNAPP Phase 1 Trial in Alzheimer''s Disease; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department